Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Lilly to acquire Hypnion

March 7, 2007

AD-923 begins U.S. phase I development for cancer breakthrough pain

March 7, 2007

Recent patents disclose novel agents for treating anxiety, depression, sleep disorders, etc.

March 6, 2007

Extension study opens for MBP-8298 in secondary progressive MS

March 6, 2007

Recent GlaxoSmithKline patents report novel analgesic agents

March 6, 2007

MAP's inhaled migraine treatment demonstrates statistically significant pain relief

March 5, 2007

Pediatric exclusivity granted for Risperdal

March 5, 2007

Innocoll files IND for CollaRx Bupivacaine Implant

March 5, 2007

Phase IIb study evaluates ganaxolone for infantile spasms

March 5, 2007

Old drug improves learning in a mouse model of Down syndrome

March 5, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...